Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypertriglyceridemia and the fibrate trials.

O Faergeman1

  • 1Department of Medicine & Cardiology, Aarhus Amtssygehus University Hospital, Aarhus, Denmark.

Current Opinion in Lipidology
|November 22, 2000
PubMed
Summary

Hypertriglyceridemia predicts cardiovascular disease risk independently of HDL cholesterol. Fibrate drugs show mixed results in reducing cardiovascular events, with ongoing trials in type II diabetes patients offering hope for clarification.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atrial fibrillation and upper limb thromboembolectomy: a national cohort study.

Journal of thrombosis and haemostasis : JTH·2011
Same author

Upper-limb thrombo-embolectomy: national cohort study in Denmark.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2010
Same author

Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.

Journal of internal medicine·2010
Same author

Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial.

Lancet (London, England)·2008
Same author

[Familial hypercholesterolemia in St. Petersburg: diversity of mutations argues against a strong founder effect].

Genetika·2007
Same author

Danish singles have a twofold risk of acute coronary syndrome: data from a cohort of 138 290 persons.

Journal of epidemiology and community health·2006

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Epidemiological studies since 1996 link hypertriglyceridemia to cardiovascular disease (CVD) risk, independent of HDL cholesterol.
  • The relationship between plasma triglycerides and CVD risk is complex, influenced by lipoprotein atherogenicity and associated non-lipid factors.
  • Moderate hypertriglyceridemia, not severe, is paradoxically linked to the highest CVD risk, challenging clinical intuition and therapeutic strategies.

Purpose of the Study:

  • To evaluate the clinical benefit of fibrate therapy in managing hypertriglyceridemia and reducing cardiovascular disease events.
  • To assess the efficacy of fibrates, which lower triglycerides and raise HDL by activating nuclear receptors, in preventing coronary artery disease deaths.
  • To review randomized clinical trials on fibrate treatment and clarify their indications, particularly in specific patient populations.

Main Methods:

  • Systematic review of 12 trials (1966-1996) involving over 21,000 patients treated with fibrates or placebo for cholesterol-lowering.
  • Analysis of four additional trials (post-1996) with 6,144 patients, including major studies like VA-HIT and BIP.
  • Examination of biochemical mechanisms of fibrates, including nuclear receptor activation, in relation to clinical outcomes.

Main Results:

  • Pre-1996 trials indicated no significant reduction in coronary deaths with fibrate therapy.
  • The VA-HIT trial showed gemfibrozil significantly reduced combined fatal and non-fatal coronary events, but not coronary deaths.
  • The BIP trial demonstrated no significant effect of bezafibrate on primary endpoints or coronary death rates.

Conclusions:

  • Clinical indications for fibrates cannot solely rely on biochemical insights or current randomized trial data.
  • Fibrate therapy demonstrates inconsistent results in reducing cardiovascular mortality, necessitating further investigation.
  • Ongoing trials in type II diabetes patients may provide crucial clarification on the role and efficacy of fibrates in CVD prevention.

Related Experiment Videos